podcasts Ratings /ratings/en/research-insights/podcasts/2020-08-05-the-sp-pharma-dose-episode-35-regeneron-pharmaceuticals-steady-growth-vs-heavy-product-concentration content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

In This List

The S&P Pharma Dose - Episode 35 - Regeneron Pharmaceuticals: Steady Growth vs. Heavy Product Concentration

COMMENTS

2021 U.S. Telecom And Cable Outlook: Rising Leverage Overshadows Economic Resilience

Leveraged Finance & CLOs Uncovered Podcast: A Deep Dive Into European Corporate Defaults

COMMENTS

2021 Global PC Shipment Forecast Raised To 0% From -7% Following Strong Expected Results In The Fourth Quarter Of 2020

COMMENTS

Credit FAQ: Anatomy Of A Credit Estimate: What It Means And How We Do It

Listen: The S&P Pharma Dose - Episode 35 - Regeneron Pharmaceuticals: Steady Growth vs. Heavy Product Concentration

S&P Global Ratings' senior pharma analyst, Ji Liu, discusses the puts and takes for our new Regeneron Pharmaceuticals ratings.